Skip to main content
VCbacked
Log inGet Started

Alchemab Therapeutics

London, United Kingdom

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

$32.0M raised
Sep 2025
Series A
BiotechnologyMedicalPharmaceutical

Top Investors

RA Capital ManagementEli LillyLightstone VenturesDementia Discovery FundSV Health Investors

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Alchemab Therapeutics

How much funding has Alchemab Therapeutics raised?
Alchemab Therapeutics has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Who are Alchemab Therapeutics's investors?
Alchemab Therapeutics's investors include RA Capital Management, Eli Lilly, Lightstone Ventures, Dementia Discovery Fund, SV Health Investors.
Where is Alchemab Therapeutics headquartered?
Alchemab Therapeutics is headquartered in London, United Kingdom.
What does Alchemab Therapeutics do?
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
What stage is Alchemab Therapeutics at?
Alchemab Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Alchemab Therapeutics — Funding & Investors." VCBacked, September 9, 2025, https://www.vcbacked.co/company/alchemab-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2025). Alchemab Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/alchemab-therapeutics
Wikipedia (cite web)
{{cite web |title=Alchemab Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alchemab-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong